Mandate

Vinge has advised VNV Global AB (publ) in connection with a directed share issue

February 19, 2021 Capital Markets and Public M&A

Vinge has advised VNV Global AB (publ), an investment company listed on Nasdaq Stockholm, in connection with a directed share issue whereby VNV Global receives approximately SEK 1,166 million in issue proceeds.

The subscription price was determined to SEK 100 per share through an accelerated book building process. The share issue was directed to selected Swedish and international investors. The company intends to use the expected net proceeds from the transaction to take advantage of investment opportunities in the near term, deploying capital in both existing investments in need of further growth capital and in to a pipeline of potential new investment opportunities.

VNV Global is an investment company with the business concept of using experience, expertise and a widespread network to identify and invest in assets with considerable potential for value appreciation. The company has a special focus on online marketplaces and businesses with strong network effects. The common shares of VNV Global are listed on Nasdaq Stockholm, Mid Cap segment, with the ticker VNV.

Vinge’s team consisted of Jesper Schönbeck, Joel Wahlberg and Eléonore Friberg.

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025